Prestige Consumer Healthcare (NYSE:PBH) reported a weaker-than-expected fourth quarter as supply constraints in eye care and shipping disruptions tied to conflict in the Middle East weighed on sales, but management said it expects a return to organic growth in fiscal 2027 and outlined a multiyear outlook supported by acquisitions, cash flow and an eventual recovery in Clear Eyes.
Chairman, President and Chief Executive Officer Ron Lombardi said the company “experienced a challenging fourth quarter that fell short of expectations,” with full-year revenue declining approximately 4%. He cited a difficult consumer environment, global conflict and shipment disruptions late in the quarter.
